When analyses were restricted only to patients with NSCLC (as most of the patients treated with PD-L1 inhibitors had NSCLC), similar, albeit non-statistically significant, trends in OR were observed (OR: 0.63; 95% CI: 0.33—1.19 for IRAEs grade ≥ 2; OR: 0.46; 95% CI: 0.19—1.12 for discontinuation due to IRAEs). This evidence concerns the gene CD274 and non-small cell lung carcinoma.